<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752699</url>
  </required_header>
  <id_info>
    <org_study_id>NPH</org_study_id>
    <nct_id>NCT01752699</nct_id>
  </id_info>
  <brief_title>Methadone in Post-Herpetic Neuralgia Pain</brief_title>
  <acronym>NPH</acronym>
  <official_title>Methadone in Post-Herpetic Neuralgia Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuropathic pain is a common condition and affecting 40 to 70% of the general population.
      Post-herpetic neuralgia is a condition almost complex and requires a multi modal treatment.
      Aim: This is a pilot proof-of-principle study designed to evaluate the use of low-dose
      methadone in post-herpetic neuralgia patients who remained refractory after first and second
      line treatment for post-herpetic neuralgia (PHN) and had indication for the association of
      an opioid agent to their current drug regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in baseline Pain</measure>
    <time_frame>baseline (visit inclusion) and three moths latter</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessing by verbal analog scale (VAS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Post-herpetic Neuralgia</condition>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm patients will take methadone 5mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm patients will take placebo pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.</description>
    <arm_group_label>Methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>patients with post-herpetic neuralgia take placebo to treat the pain symptoms.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic (&gt;6 months) symptomatic PHN

          -  with visual analogical scale &gt;40/100mm

          -  use of first and second line drugs (tricyclic antidepressants, venlafaxine and
             gabapentinoids)

        Exclusion Criteria:

          -  Don't full the criteria above
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Daniel Ciampi Araujo de Andrade</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>neuropathic pain,</keyword>
  <keyword>post-herpetic neuralgia,</keyword>
  <keyword>methadone,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
